{"id":59954,"date":"2024-02-28T06:25:37","date_gmt":"2024-02-28T06:25:37","guid":{"rendered":"https:\/\/medsname.com\/palip-xr\/"},"modified":"2026-04-30T10:23:52","modified_gmt":"2026-04-30T10:23:52","slug":"palip-xr","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/palip-xr\/","title":{"rendered":"Palip XR"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Palip XR (Paliperidone 3 \/ 6 \/ 9 mg XR, extended-release) is an atypical antipsychotic for schizophrenia and schizoaffective disorder. Active metabolite of risperidone, dosed once daily via OROS osmotic-pump tablet. Largely renally cleared \u2014 dose-adjust in renal impairment.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Palip XR at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

What Palip XR is and how it works<\/h2>\n

Palip XR is a paliperidone extended-release tablet supplied by Sun Pharma. Available strengths: 3 \/ 6 \/ 9 mg XR<\/strong>. Paliperidone is the major active metabolite of risperidone (9-hydroxyrisperidone). Pharmacologically very similar \u2014 strong D2 and 5-HT2A antagonism, prolactin elevation, EPS at higher doses \u2014 but with two practical differences: (1) the OROS extended-release formulation produces a flat 24-hour plasma curve (smoother tolerability than risperidone IR), and (2) paliperidone is largely renally cleared (75%) rather than hepatically metabolised, so it is unaffected by CYP-altering drugs but requires dose adjustment in renal impairment.<\/p>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikace<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Schizophrenia (adult)<\/td>\n6 mg OD morning<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Schizophrenia (adolescent \u2265 12 y, \u2265 51 kg)<\/td>\n3 mg OD<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Schizoaffective disorder<\/td>\n6 mg OD<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Renal impairment (CrCl 50\u201380)<\/td>\n3 mg OD<\/td>\nup to 6 mg<\/td>\n6 mg<\/td>\n<\/tr>\n
Renal impairment (CrCl 10\u201350)<\/td>\n1.5 mg OD<\/td>\nup to 3 mg<\/td>\n3 mg<\/td>\n<\/tr>\n
Ren\u00e1ln\u00ed insuficience (CrCl < 10)<\/td>\nnedoporu\u010duje se<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take whole \u2014 do not crush, chew, or split. The OROS osmotic pump shell will pass intact in stool \u2014 this is normal and expected.<\/p>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nFDA black-box \u2014 dementia-related psychosis<\/strong><\/p>\n

All atypical antipsychotics carry an FDA black-box warning for increased mortality (mostly cardiovascular and infectious) when used to treat behavioural disturbance in older adults with dementia. Atypicals are not approved for dementia-related psychosis or agitation<\/strong>. Use in this population is off-label, last-resort, time-limited, and requires explicit risk-benefit conversation.<\/p>\n<\/div>\n

\nHyperprolactinaemia (similar to risperidone)<\/strong><\/p>\n

As an active risperidone metabolite, paliperidone produces the same prolactin elevation: amenorrhoea, galactorrhoea, sexual dysfunction, and long-term bone-density loss. Monitor as for risperidone; switch to a prolactin-sparing atypical (aripiprazole, quetiapine) if symptomatic.<\/p>\n<\/div>\n

\nEPS \/ dose-dependent<\/strong><\/p>\n

Above 6 mg\/day, EPS and akathisia rise in frequency. Dose-dependent.<\/p>\n<\/div>\n

\nGI obstruction caveat<\/strong><\/p>\n

The non-deformable OROS tablet is theoretically problematic in pre-existing severe GI narrowing (severe Crohn’s strictures, oesophageal stricture, prior bowel resection). Rare clinically, but worth noting.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n